Market Intelligence, Clinical Progress, and High-Purity Reagents for Polyamine Metabolism and Ferroptosis-Targeted Cancer Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for SAT1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SAT1 Recombinant Protein (Active) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. E. coli expressed active enzyme. |
View SAT1 Products |
| Gene Delivery | SAT1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and overexpression validation. |
View SAT1 Products |
| Benchmark Ab | Anti-SAT1 Recombinant Antibody Recombinant positive control for Western Blot, IHC, and FACS. |
View SAT1 Products |
| Validator | SAT1 siRNA Set For knockdown verification in target specificity assays. |
View SAT1 Products |
| Related Target A | ODC1 Ornithine Decarboxylase 1, the key rate-limiting enzyme in polyamine synthesis, acting upstream of SAT1. |
View ODC1 Products |
| Related Target B | SMOX Spermine Oxidase, catalyzing the oxidation of spermine, highly synergistic with SAT1 in polyamine catabolism. |
View SMOX Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Enzymatic Activity & HTS Screening | High-purity, active recombinant SAT1 protein with verified kinetic parameters and batch-to-batch consistency. |
| Selectivity Counter-Screening | Homolog panel proteins (including SAT2/SSAT2) strictly verified by mass spectrometry to exclude off-target effects. |
| Lack of Controls | Recombinant positive control antibodies and sequence-verified positive control plasmids included. |
| False Positives | Validated siRNA sets included for cellular target knockdown and specificity validation. |
Live SAT1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for SAT1 therapeutics is intensifying, with major players shifting focus from traditional metabolic inhibitors to induction of ferroptosis and modulation of the tumor microenvironment. As first-generation therapies reach the clinic, the next wave of R&D is targeting SAT1 activation to selectively trigger iron-dependent cell death in treatment-resistant solid tumors, as well as developing selective inhibitors to alleviate stroke-induced brain injury and muscle wasting.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Activators | Academic Consortia, Biotech Startups | Glioblastoma, Melanoma, Refractory Solid Tumors | High-throughput enzymatic assays requiring highly active recombinant SAT1 protein. |
| Small Molecule Inhibitors | Pharmaceutical Developers | Ischemic Stroke, Cachexia, Inflammatory Diseases | Selectivity profiling against SSAT2 using purified homolog panels. |
| RNA Therapeutics / ASO | RNAi Therapeutics Specialists | Oncology, Fibrotic Diseases | Validated siRNA and lentiviral vectors for cellular target knockdown and functional rescue assays. |